Louis O. BRENNER, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Ranitidine is a histamine-2 receptor antagonist that has been approved for use in the United States since 1983. It is more potent than Cimetidine and has not been reported to cause complications, especially agranulocytosis (1).
An 86-year-old white woman was hospitalized on 8 May 1985 with fever. Seven weeks earlier she had had an uncomplicated takedown of a colostomy. At that time, abnormal hepatic function tests and hyperglycemia were noted, but a complete blood count and differential were normal. Ten days before the current admission she was treated with ranitidine, 150 mg twice daily, and with an
BRENNER LO. Agranulocytosis and Ranitidine. Ann Intern Med. 1986;104:896–897. doi: 10.7326/0003-4819-104-6-896_2
Download citation file:
Published: Ann Intern Med. 1986;104(6):896-897.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use